HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-κB signaling pathway

Chen,Wei; Liu,Xiaoqun; Yuan,Sujuan; Qiao,Tiankui

doi:10.3892/ol.2018.7800

HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-κB signaling pathway

Authors:
- Wei Chen
- Xiaoqun Liu
- Sujuan Yuan
- Tiankui Qiao
View Affiliations

Affiliations: Department of Oncology, Jinshan Hospital, Fudan University, Shanghai 201500, P.R. China
Published online on: January 16, 2018 https://doi.org/10.3892/ol.2018.7800
Pages: 3883-3889

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although cisplatin (CDDP) is widely used for non-small-cell lung cancer (NSCLC) treatment, resistance remains a major problem that restricts its efficacy. Therefore, identification of drugs that reverse or prevent resistance to CDDP in NSCLC has been a focus of a number of studies. The results of the present study revealed the effect of heat shock protein family A member 12B (HSPA12B) overexpression on chemoresistance in A549 cells in vitro. The effect of HSPA12B overexpression on chemoresistance in mice bearing A549 xenografted tumors was then determined via stable HSPA12B transfection. Finally, the effects of HSPA12B overexpression on the phosphorylation of protein kinase B (Akt) and nuclear factor-κB inhibitor α (IκBα), and the expression of the anti‑apoptotic protein B‑cell lymphoma 2 (Bcl‑2) and the pro‑apoptotic protein cleaved caspase‑3 were determined by western blot analysis. The results demonstrated that HSPA12B overexpression increased resistance to CDDP in NSCLC cells in vivo and in vitro by promoting cell growth and inhibiting CDDP‑induced apoptosis. Mechanistically, this effect was mediated by the upregulation of phosphorylated (p‑)Akt, p‑IκBα and Bcl‑2 and the downregulation of cleaved caspase‑3. Therefore, the present study provides useful information pertaining to the identification and targeting of a CDDP‑resistant population, and the development of potential therapeutics to improve the current treatment modalities in NSCLC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Travis WD, Brambilla E and Riely GJ: New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol. 31:992–1001. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ma G, Cai H, Gao L, Wang M and Wang H: sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo. World J Surg Oncol. 13:802015. View Article : Google Scholar : PubMed/NCBI
4	Yuan JM, Li XD, Liu ZY, Hou GQ, Kang JH, Huang DY and Du SX: Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev. 12:3465–3469. 2011.PubMed/NCBI
5	Koberle B, Tomicic MT, Usanova S and Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
6	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
7	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
8	Law S and Wong J: The current management of esophageal cancer. Adv Surg. 41:93–119. 2007. View Article : Google Scholar : PubMed/NCBI
9	Han Z, Truong QA, Park S and Breslow JL: Two Hsp70 family members expressed in atherosclerotic lesions. Proc Natl Acad Sci USA. 100:pp. 1256–1261. 2003; View Article : Google Scholar : PubMed/NCBI
10	Ren A, Yan G, You B and Sun J: Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res. 68:2266–2274. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yoshidomi K, Murakami A, Yakabe K, Sueoka K, Nawata S and Sugino N: Heat shock protein 70 is involved in malignant behaviors and chemosensitivities to cisplatin in cervical squamous cell carcinoma cells. J Obstet Gynaecol Res. 40:1188–1196. 2014. View Article : Google Scholar : PubMed/NCBI
12	Steagall RJ, Hua F, Thirunazukarasu M, Zhan L, Li C, Maulik N and Han Z: Abstract 3600: HspA12B promotes angiogenesis through suppressing AKAP12 and up-regulating VEGF pathway. Circulation. 118 Suppl 18:S4492008.
13	Ma H, Lu T, Zhang X, Li C, Xiong J, Huang L, Liu P, Li Y, Liu L and Ding Z: HSPA12B: A novel facilitator of lung tumor growth. Oncotarget. 6:9924–9936. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zhang B, Liu ZM, Hao FG and Wang M: siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice. Eur Rev Med Pharmacol Sci. 18:1595–1601. 2014.PubMed/NCBI
15	Bayne K: Revised guide for the care and use of laboratory animals available. American physiological society. Physiologist. 39:199–208, 111. 1996.PubMed/NCBI
16	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
17	Su J, Wu S, Tang W, Qian H, Zhou H and Guo T: Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling. Mol Carcinog. 55:1822–1832. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lippard SJ: Platinum, Gold, and Other Metal Chemotherapeutic Agents. 209. American Chemical Society; Washington, DC: 1983, doi: 10.1021/bk-1983-0209. View Article : Google Scholar
19	Azijli K, Weyhenmeyer B, Peters GJ, de Jong S and Kruyt FA: Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 20:858–868. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wang M, Liu ZM, Li XC, Yao YT and Yin ZX: Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother. 25:162–169. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yang M, Huang J, Pan HZ and Jin J: Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med. 22:489–496. 2008.PubMed/NCBI
22	Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI